Fiscal Year Ending March 2026 Financial Results Supplementary Material

Performance Overview

For the fiscal year ending March 2026, net sales reached 718.163 billion yen, a 5.9% increase from the same period last year, surpassing the plan by 2.6%. Operating profit was 24.482 billion yen, a decrease of 1.2% YoY, falling short of the plan by 5.8%. Ordinary income increased by 1.2% YoY to 26.331 billion yen. However, net income attributable to owners of the parent decreased by 11.5% YoY to 13.394 billion yen. Gross profit was almost flat at 66.703 billion yen compared to the same period last year.

Segment Performance

Total segment sales were as follows: Total Pack Produce (TPP) at 136.604 billion yen (up 2.6% YoY), Medical Supply (MSP) at 509.569 billion yen (up 7.3% YoY), Life Care (LC) at 37.322 billion yen (up 1.8% YoY), and Dispensing Pharmacy (PH) at 34.666 billion yen (up 3.6% YoY). Operating profit by segment was: TPP at 10.812 billion yen (▼10.0% YoY), MSP at 7.484 billion yen (up 7.4% YoY), LC at 2.216 billion yen (up 1.2% YoY), and PH at 4.004 billion yen (up 16.9% YoY).

Management Plan for Fiscal Year Ending March 2027

For fiscal year ending March 2027, sales are projected to be 740.000 billion yen (up 3.0% YoY), operating profit 26.000 billion yen (up 6.2% YoY), ordinary income 26.500 billion yen (up 0.6% YoY), and net income attributable to owners of the parent 16.000 billion yen (up 19.5% YoY). The dividend per share is planned at 65 yen, with a target dividend payout ratio of 37.4%.